Exploring Evolving Antiplatelet Paradigms in Acute Myocardial Infarction

Exploring Evolving Antiplatelet Paradigms in Acute Myocardial Infarction is organized by Efficient LLC.

Course opens: 08/27/2025
Course expires: 08/27/2026

Description:
This educational activity aims to provide cardiology professionals with critical insight into evolving antiplatelet paradigms for managing acute myocardial infarction (AMI). Through an interactive, case-based format, participants explore the clinical profiles of current and emerging antiplatelet therapies (e.g., P2Y12 inhibitors, GP IIb/IIIa inhibitors), evaluate available evidence surrounding pretreatment strategies including the potential utility of emerging therapies for this setting, and assess the applicability of dual anti-platelet therapy (DAPT) de-escalation approaches. Expert faculty guide learners in applying evidence-based strategies to clinical scenarios, enabling them to make informed decisions that balance ischemic and bleeding risks in AMI care.

Learning Objectives:
Upon completion of this activity, the learner should be able to:

• Differentiate the clinical profiles of antiplatelet agents (e.g., P2Y inhibitors, GP IIb/IIIa inhibitors) to inform evidence-based treatment selection in ACS management.
• Assess the rationale supporting and opposing pretreatment in ACS to determine its clinical relevance and applicability in patient care.
• Analyze the mechanisms efficacy, safety, and therapeutic potential of emerging pretreatment agents in late-stage development to prepare clinicians for their potential integration into ACS care, if approved in the future.
• Evaluate DAPT de-escalation strategies for eligible patients by balancing ischemic protection with bleeding risks to reduce treatment burden.